medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 2

<< Back Next >>

Gac Med Mex 2003; 139 (2)

Developments in Transfusional Medicine

Introduction.
Clinical Indications for Plasma Use.
Transfusion in the Cardiovascular Surgery Patient.
Pathogen Inactivation Methods in Cellular Blood Products.

Bravo-Lindoro AG, Lomelí-Guerrero A, Mejía-Domínguez AM

Language: Spanish
References: 35
Page: 20-27
PDF size: 140.02 Kb.


Text Extraction

No abstract


REFERENCES

  1. Lomelí GA, Velásquez FA. Terapéutica transfusional. En: Ruiz-Argüelles GJ fundamentos de Hematología. Ed. Panamericana, 1998. 343-362.

  2. Drohan WN, Hayer LW. Plasma protein products. En: Anderson K.C. Scientific basis of transfusion medicine, implications for clinical practices. W.B.Saunders Co. Philadelphia 1994. 381-397.

  3. Consensus Conference. Fresh frozen plasma. Indications and risks. JAMA 1985; 253: 551-553.

  4. Pita R, Cabrera CB, Ortega ZC. Análisis de la transfusión de PFC en un Hospital regional de concentración durante seis meses consecutivos. Rev. Invest. Clin. 1999; 51:89-92

  5. Rosen NR, Bates LH, Herod G. Transfusion therapy: improved patient care and resource utilization. Transfusion 1993; 33: 341-347

  6. Byrnes JJ, Moake JL, Klug P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Amer J Hemat 1990; 34: 169-174.

  7. Transfusion practical in Cardiac Surgery, American Association of Blood Banks, Arlington Virginia, 1991

  8. Blood Transfusion Therapy American Association of Blood Banks. 2002

  9. Recomendaciones para la terapia transfusional de sangre y sus componentes, Consenso de Expertos En Medicina Transfusional, Comité de Medicina Transfusional de la Agrupación Mexicana para el Estudio de la Hematología. 2001.

  10. Pautas para programas de calidad en los servicios de transfusión de sangre. Organización Mundial de la Salud. 1993.

  11. Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cell. Transfusion 39: 701-710. 1999.

  12. Attie. Zabal, Buendía. Cardiología Pediátrica, Diagnóstico y Tratamiento, Ed. Panamericana, 2001.

  13. Mejía DAM. Manual de procedimientos, Banco de Sangre, Instituto Nacional de Cardiología “Ignacio Chávez” 2000.

  14. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumnholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med.2001, 345: 2130-1236.

  15. Hebert FC, Yetisir E, Martín C, Bajchman MA, Wells G, Marshall J, Tweedate M, Pagliarello G, Schweitzer I. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? . Crit Care Med. 2001, 29: 227-234.

  16. Spahn DR, Seifert B, Seifert B, Pasch T, Schmid ER. Effects of chronic mechanisms during acute isovolaemic haemodilution in patients with coronary artery disease. Br.J. Anaesth., 1997, 78: 381-385.

  17. Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, Noveck H, Strom BL. Effect of anaemia and cardiovascular disease on surgical mortality and morbility. Lancet 1996, 348: 1055-1060.

  18. Lee TH. Reducing cardiac risk in noncardiac surgery. N Engl. J Med., 1999, 341: 1838-1840.

  19. Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery, erythropoietin and antifibrinolytics. Can J Anesth. 2001, 48: S24-S31.

  20. Spahn DR. Perioperative transfusion triggers for red blood cells. Vox Sang 2000, 78: 163-166.

  21. Walsh TS, McClelland B. Perioperative Triggers for red cell transfusion. Vox Sang. 2002, 82: 215-226.

  22. Cabrera PA, Cruz BR, Rodríguez RK, Domínguez RL,Gaezón RE. Uso del ácido tranexámico durante el proceder quirúrgico durante la cardiocirugía. Rev Latinoamer. Tecnol Extracorp. 2002, 9(2), 10.38-10.45.

  23. Correa R, Crosara DD, Sánchez JD. Ventajas de la autotransfusión de plasma enriquecido en plaquetas en cirugía cardiovascular. Cir. Cardiov. 1997, 4(1): 21-26.

  24. Zapata MG, Reyes BN, Mendoza LC. Riegos de infección en transfusión sanguínea. En: Tópicos Selectos en Transfusión Sanguínea. Banco Central de Sangre CMN Siglo XXI. IMSS. Ed. Prado 2002. 153-161.

  25. Murphy WG. Disease transmission by blood products: Past, Present and future. Pathophysiol Haemost Thromb 2002;32 (suppl 1):1-4.

  26. Goodnough L.T. Transfusion medicine .Looking to the future. Lancet 2003.11;361:161-9.

  27. Blajchman A. Bacterial Contamination of Blood Units: Emerging Concerns and Evolving Strategies. In The safety of the blood. Ed.Hillyer.C:1999: 18-21.

  28. Corash L. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Bailliere ´s Clinical Haematology. 2000; 13 : 549-563.

  29. Corash L. Virus “Safe” products/ pathogen reduction Chapter 20 in: Blood banking and transfusion medicine .Hillyer. C.D. 241-259. 2003 ed. Churchill Livingston.

  30. Lin L, Wiesehahn GP, Morel PA, Corash L. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood 1989;74:517-525.

  31. Dick R, Hans G, Jean-Pierre C, et al. Transfusion of pooled Buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euro SPRITE trial. Blood. 2003 ;101: 2426-2433.

  32. Corbin F. Pathogen inactivation of blood components current status and introduction of an approach using riboflabin as a photosensitizer. International Journal of Hematology. 2002. Suppl. II. 253-257.

  33. The council of Europe. Pathogen inactivation of labile blood products. Transfusion Medicine,2001; 149-175.

  34. Wagner SJ, et al. Preservation of red cell properties after virucidal phototreatment with dimethylene blue. Transfusion 1998;38:729-737.

  35. Wainwright M. Pathogen Inactivation in Blood Products. Curr Med Chem. 2002. 9:127-213.




2020     |     www.medigraphic.com